ESCAP-2020-CPHG: Treatment Strategies Follow-up Implemented During the First Three Years Following Primary Lung Cancer (PLC) Diagnosed in KBP-2020-CPHG Cohort Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04419155

Acronym

ESCAP-2020

Enrollment

5000

Registered

2020-06-05

Start date

2020-01-01

Completion date

2023-12-31

Last updated

2020-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

The prognosis for primary lung cancer (PLC) is very limited. In France, patients diagnosed for PLC in 2010 and followed in Respiratory Medicine or Oncology department of a General Hospital Centre had a 5-year survival rate of 12.7% (vs 10% in 2000). Over the last ten years, substantial improvements have been made both in terms of diagnostic (immunohistochemistry and molecular biology) and therapeutic. New treatments have been marketed and are now available in clinic. New therapeutical strategies have been launched and have proved their efficacy in clinical studies or meta-analyses, generally increasing the survival rate of patients by a few months. However, little information still exists on the use and effectiveness of these molecules in clinical practice. The CPHG proposes to complete the information collected during KPB-2020-CPHG study by the ESCAP-2020-CPHG study that is a follow-up of therapeutical strategies over the first 3 years of treatment. This study should improve knowledge of the PLC treatment management in General Hospital Centres.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Age ≥ 18 years * Primary Lung Cancer histologically (or cytologically or presence of a mutation on liquid biopsy with compatible imaging) proven between January 1st and December 31st, 2020\* * Follow-up by a lung specialist at a General Hospital * Oral informed consent \* date of collected sample

Exclusion criteria

* Age \< 18 years * Secondary lung cancer * Recurrence of same histological type PLC- left to the investigator discretion according to the clinic and the imagery * Previous enrolment in the study * Freedom deprived patient following a legal or administrative decision * Patient unable to give his(her) consent

Design outcomes

Primary

Measure	Time frame	Description
Describe therapeutical strategies implemented by pulmonologists in Respiratory Medicine or Oncology department of a General Hospital Centres during the first three years following PLC diagnosed in KBP-2020-CPHG cohort patients.	3 years	Data collected for the ESCAP-2020-CPHG study: \- All treatments administered

Countries

France

Outcome results